{"name":"Sinew Pharma Inc.","slug":"sinew-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Panadol®","genericName":"Panadol®","slug":"panadol","indication":"Mild to moderate pain","status":"marketed"},{"name":"SafeTynadol®","genericName":"SafeTynadol®","slug":"safetynadol","indication":"Pain relief and fever reduction (marketed indication presumed)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Naldebain","genericName":"Naldebain","slug":"naldebain","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Naldebain","genericName":"Naldebain","slug":"naldebain","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Panadol®","genericName":"Panadol®","slug":"panadol","phase":"marketed","mechanism":"Panadol (paracetamol/acetaminophen) reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.","indications":["Mild to moderate pain","Fever reduction","Headache","Muscular aches"],"catalyst":""},{"name":"SafeTynadol®","genericName":"SafeTynadol®","slug":"safetynadol","phase":"marketed","mechanism":"SafeTynadol® is a modified formulation of acetaminophen designed to reduce hepatotoxicity risk through enhanced safety mechanisms.","indications":["Pain relief and fever reduction (marketed indication presumed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNY1lHVnJhNzVSNWppd0tSbWo3dlZmeDVBbWs1enluRGxfSzFaZ2dsaXdxd3I0QUd4emQ5NGNjc0VITk1xcEF4TUluX1NFckdDWm5xbU9HZF9RQllxY1BBVW1TbTVKbkVLa3RQQTRsZlJWTUR1UWUweGQxcERDX3JibG9yM3BMdWlwUVZvMVdZWjZrRnlBNWVzVFR6MFh3dHcyaGtGM0FyUVB1aGFFV3lGU3VfSlRCQzVsMThwMW1Rclo5dXNkOWZxZDJ3WXNfU1hm?oc=5","date":"2026-04-04","type":"earnings","source":"marketscreener.com","summary":"Sinew Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com","headline":"Sinew Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBZQ2Y2UnZJLWtZT041Z0RTVXdPVTcxaXM3QnBQX3R0dXFQS3VwSldVUGxxckVPU0VpZHFqMlpaOS10aHB4VjVYUzM1TDB4eWdhN0Mwbm5tWW1sbEExM0ZIQ0ZPaWc?oc=5","date":"2025-11-26","type":"pipeline","source":"Market.us","summary":"Prescription appetite suppressants - Market.us","headline":"Prescription appetite suppressants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNY1JaSEFaVnFfU1RFUF85NFdPTWVkNWpVR1V5dXIxSnZiUGZZV0w2andLOEdNSXUza3FUbnl2N1dQZThDYTZ0eXV0a2V3c1JSMjJqek5aNzd1MGY1M1JkNmZreDJ3cWpRTXR4aWZTLXF1cEowS0xoMnJla3NSd1BReEhORDNmRmI5U1djd3lwNDB0UG5kM0ZzMmNxXzJpSE9YNXRyWnVuOFVDb09Ocld3djFIZF9qd2RweUNPeE5xWlVxWlZUdXUwMGlKdUg5NXVsa1E?oc=5","date":"2025-07-30","type":"pipeline","source":"prnewswire.com","summary":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight - prnewswire.com","headline":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPLXA1VDlORlNsSWJ0akRIM1BDUldVcGZuRzJhNjkzMzhVUHhfMHQ4d04tMGtERDlUb0VvMmRHSHdwU3V5ZUxuM1dQb3RLV2xsbUdValpqYTdLbDNtWWZMMVhQZE9maW45V0xleG9pbjhhMFo1RW13cEhBTG9KcTVxRWR1NmVCSG9ZVEgwdVZUMVdGM2p6N2hoYm9zbmpvUWZQUmpwVmQ4blcwQzZMVUhndEQyQ3B5QTJuSi1MX0dMdlo1SXZCbFNZUllpdUpOekJKakJ5TUV6Qm1DSTc2OVBUUlo4eVhmOFJCckpyakpyeXFqVjRCQW9sQTRhd1Y0emtuR1ZrdVJXc2pMV1h1N2VYTl81dHQzalZGQ0xZRXFpSFlwdU53M3c?oc=5","date":"2025-05-13","type":"pipeline","source":"prnewswire.com","summary":"Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - prnewswire.com","headline":"Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Tre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOaGMwZmh0SWVNM2V1elF0Ykx4R2FyWTc3emlSckwzUmg5QUEtYmpnSDFyQmJiVWI2czhPM1JXdW50UnAyamNOT1FCSXVrNm1ma1BSVldDbnlNbUNleXR4bWRNWmtTZUhyT05DVHlKdDd0S3U5U0dQVXZiV3NJTW5vdkFYSzVOektrVXRBWVplYjQ3UmNVZWd2VVRUQmhHT0k0bjFUVk13NDNETjJmSXh1TFczMm1uWWZJTU1HN25FUWgwdW9mc1ZLWl9iT0RTWWdlWFpkeVpZOWtGUnQ3eWRNUVZZeGJIQ2puSzBTclF5WExQYnAyQktkVWxIbFBQWEtKN1VXZjVTZ21mN1BlZ0QxanJnMmhfeDA2?oc=5","date":"2025-01-30","type":"pipeline","source":"prnewswire.com","summary":"Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - prnewswire.com","headline":"Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOZVRUM09NbTMwZlBrNENqbXZUTnl1Y0VLajdSZG9iZGdfQ3Nabl95RFJ5R3F3UUVGRURYaFBsTmZRaDdoY21NWmU3WEhZWXBldmFiYk1QeEpjZGlwN2lvWWpvY1QyaUhIQVZ0MU9YOHNjbDR0d3ZSckNWVUZDUkx5dkl0NTAybjVfQ2Z2OVRLbUFKa2hRUEFOZ0lqQjl6aG9QYzJHQkZZNTBLYUdyZXNmcmRFaGhYQ29sOXhZQnJCOGlKa0VOOGR0STZzTFBmZW5QOE0xN3pKMGlLcV9XSFBGMGp4X05EUERPdHRsaE1SdmFBWFloM05vbTZXSFNFdw?oc=5","date":"2024-01-17","type":"pipeline","source":"IANS","summary":"Indo-Asian News Service - IANS","headline":"Indo-Asian News Service","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPOXduWVp5b19OWFd5R1BzMkZvcldONC0xVEc3NTh1aEhJLU5HV1Q0Ni0zZlVxUGFzemZoRzBWdmVPOUJ0eXVnZVdKeGtQVTlQMmJNdEwzaWptc2puZTg2dFM5Vkk1XzlUX3R6bjllTTRVeGhzcGlzVTdkNXk0amx3bS1HWUY1UHdWOFlCNnhqS2ZlLVVhRmdHQWhDV3VncVRDcUlpUnU5b204Q3BEazN3bXRBclJZdDByMjQxNDZCX3RIWG9UVWc3YlV6Uk9UWGUyeGUyUmhlbEV0ZjVfYlJmbGVYMDR5YXBFeXAw?oc=5","date":"2023-07-12","type":"pipeline","source":"prnewswire.com","summary":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - prnewswire.com","headline":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5WYlA4bUtLUk5na1gxSmREelVIN091cmstZ1VWeE91SklnVU5UYkpQOUxXVU81OEFvLU9xWU0xNVoycHp1MjNIQXpPQnFBLS1iNDF1OUZ4Zw?oc=5","date":"2020-01-09","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Healthconn Corp. (6665.TWO) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Healthconn Corp. (6665.TWO) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}